Cartesian Therapeutics (RNAC) said Friday it enrolled the first participant in its phase 3 myasthenia gravis study that will evaluate Descartes-08, the company's lead cell therapy candidate for autoimmune disease.
The study will evaluate Descartes-08 versus placebo given as six once-weekly outpatient infusions without preconditioning chemotherapy in about 100 participants who have acetylcholine receptor autoantibody positive myasthenia gravis, the company said.
The trial's primary endpoint will assess the proportion of participants with an improvement in myasthenia gravis activities of daily living score of at least three points at month four compared with placebo, the company added.
Price: 9.63, Change: -0.37, Percent Change: -3.70
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.